A research filter, not a predictor — not financial advice. Grades rank growth stocks on evidence-based quality signals from end-of-day data; they are not buy/sell calls or price forecasts. Always do your own research.
Privia Health Group, Inc. PRVA
Weak broader-coverage candidate · Privia Health Group, Inc.
On FrontierLab's discovery record since 2026-08-12 (9 days ago) — when this name first surfaced. (distinct from the snapshot date below)
Auto-graded broader coverage — sourced by an automated screen and graded on default bands, not the sector-calibrated bands the curated screener uses. A "Weak" here is NOT the same bar as a curated grade; these are auto-screened candidates for your own research, shown as of their surface date (2026-08-14), not the curated Frontier signal.
Key quality signals
| Revenue growth (YoY) | 24.1% |
|---|---|
| Gross margin | 7.6% |
| Gross profits / assets | 0 |
| Rule of 40 | 26 |
| Net margin | 1.9% |
| Cash runway (months) | 120 |
| PEG | 1.1 |
| Price / sales | 1.2 |
Quality checklist
- ✓ Revenue growth — 24.1% (pass ≥ 20%)
- ✗ Gross profits / assets — 0 (pass ≥ 0.33)
- ✗ Gross margin — 7.6% (pass ≥ 60%)
- ~ Cash generation
- ~ Share dilution — 2.6%
Fundamentals — snapshot as of 2026-08-14
| Stage | Established |
|---|---|
| Share issuance (YoY) | 2.6% · modest issuance |
| Moat | — |
| TAM | — |
| P/E (trailing) | 100.3 |
| EPS (trailing) | $0.22 |
| Burn multiple | — |
| Gross-margin trend (pts) | -2.2 |
| Cash / assets | 0.28 |
| Net debt / EBITDA | -5918.9 |
| Statements as of | Q2 FY2026 · filed 2026-08-06 |
Momentum context — a snapshot from 2026-08-14, not current
| Price at surface | $21.76 (as of 2026-08-14) |
|---|---|
| 52-week range | $19.53 – $28.82 |
| % off 52-wk high | -24.5% |
| RSI (14) | 30 |
| Relative volume | 0.8× |
Risk flags
← All broader-coverage names · Curated names → · Open the interactive screener →
Data as of 2026-08-14 (end-of-day). How grades are computed →